Active Ingredient History
Galantamine (RAZADYNE®, galantamine hydrobromide) is a benzazepine derived from norbelladine. It is found in Galanthus and other Amaryllidaceae. It is a reversible, competitive acetylcholinesterase inhibitor that is used for the treatment of mild to moderate dementia of the Alzheimer’s type. Although the etiology of cognitive impairment in Alzheimer’s disease is not fully understood, it has been reported that acetylcholine-producing neurons degenerate in the brains of patients with Alzheimer’s disease. The degree of this cholinergic loss has been correlated with degree of cognitive impairment and density of amyloid plaques (a neuropathological hallmark of Alzheimer’s disease). While the precise mechanism of galantamine’s (RAZADYNE®, galantamine hydrobromide) action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. If this mechanism is correct, galantamine’s (RAZADYNE®, galantamine hydrobromide) effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact. There is no evidence that galantamine (RAZADYNE®, galantamine hydrobromide) alters the course of the underlying dementing process. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Alzheimer Disease (approved 2001)
AIDS Dementia Complex (Phase 2)
Alzheimer Disease (Phase 4)
Anxiety Disorders (Phase 3)
Autism Spectrum Disorder (Phase 3)
Autistic Disorder (Phase 3)
Bipolar Disorder (Phase 4)
Brain Diseases (Phase 3)
Brain Injuries, Traumatic (Phase 2)
Buprenorphine (Phase 1)
Cholinesterase Inhibitors (Phase 4)
Cocaine-Related Disorders (Phase 2)
Cognition Disorders (Phase 3)
Cognitive Dysfunction (Phase 2)
Dementia (Phase 4)
Dementia, Vascular (Phase 4)
Depression (Phase 4)
Endothelial Cells (Phase 2)
Fasting (Phase 1)
Frontotemporal Dementia (Phase 2)
Galantamine (Phase 4)
Genetic Diseases, Inborn (Phase 2)
Head Injuries, Closed (Phase 4)
Healthy Volunteers (Phase 1)
Hypertension (Phase 4)
Insulin Resistance (Phase 1)
Lewy Body Disease (Phase 3)
Memory (Phase 1)
Memory Disorders (Phase 4)
Mental Disorders (Phase 3)
Nervous System Diseases (Phase 3)
Obesity (Phase 1/Phase 2)
Oxidative Stress (Phase 1)
Pharmacokinetics (Phase 1)
Post-Traumatic Headache (Phase 4)
Psychophysiologic Disorders (Phase 3)
Psychotic Disorders (Phase 4)
Schizophrenia (Phase 4)
Smoking (Phase 1)
Stress Disorders, Post-Traumatic (Phase 2)
Stroke (Phase 4)
Subarachnoid Hemorrhage (Phase 1/Phase 2)
Substance Withdrawal Syndrome (Phase 1)
Tardive Dyskinesia (Phase 4)
Tic Disorders (Phase 4)
Tobacco Use Disorder (Phase 2)
Tourette Syndrome (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
